Newsfileยท2025-11-12 00:34Core Points - Rosen Law Firm is reminding investors of aTyr Pharma, Inc. to secure counsel before the December 8, 2025 lead plaintiff deadline for a securities class action [2][4] - Investors who purchased aTyr Pharma common stock during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6] - The lawsuit alleges that aTyr Pharma made misleading statements regarding the efficacy of its drug Efzofitimod, which led to investor damages when the truth was revealed [6] Company Information - aTyr Pharma, Inc. is currently facing a class action lawsuit due to allegations of providing false and misleading information about its drug's capabilities [6] - The Rosen Law Firm has a strong track record in securities class actions, having recovered hundreds of millions of dollars for investors and being recognized for its success in this field [5] Legal Process - Investors interested in joining the class action can do so by contacting the Rosen Law Firm through their website or phone [4][7] - It is important to note that no class has been certified yet, and investors are not represented by counsel unless they retain one [8]